Advertisements


Previewing Q3 Earnings Season After Rough Reports from Nike and Micron

We are starting to look at these early reports from FedEx, Nike, Micron and others for their fiscal periods ending in August as giving us a preview of what likely lies ahead as the banks kick-off the Q3 reporting cycle in about two weeks We had been skeptical about extrapolating too much from FedEx’s FDX downbeat quarterly numbers as we see a big part of the problems as FedEx specific. But FedEx is hardly alone in pointing towards a cloudier horizon.We don’t typically associate Nike NKE with management and operational missteps, but we just heard them tell us about a large inventory overhang that’s having negative implications for margins and profitability. Part of the +44% jump in Nike’s inventory is reportedly related to apparel whose movement through the company’s supply chain was impacted by ongoing logistical challenges.We don’t know the details, but it’s fair to assume that some part of the inventory buildup is related to softening demand. After all, the U.S. Fed’s ongoing tightening cycle is directed at crimping aggregate demand as a way to bring down inflationary pressures.Nike’s inventory problem validates what we heard from retailers in the Q2 reporting cycle. Chipmaker Micron MU is faced with a comparable issue that forced it to cut guidance and slash CapEx to bring chip supplies in alignment with market demand that has come down as a result of weakening PC, tablet and smartphone sales.We are starting to look at these early reports from FedEx, Nike, Micron and others for their fiscal periods ending in August as giving us a preview of what likely lies ahead as the banks kick-off the Q3 reporting cycle in about two weeks. For the record, we and other data vendors count these early reports as part of the Q3 earnings season.Through Friday, September 30th, we have seen a total of 15 S&P 500 members report results in recent days, including the aforementioned companies. We have another 4 index members on deck to report results this week, including Conagra CAG and Constellation Brands STZ.Total earnings for these 15 S&P 500 companies that have reported results are down -8.3% from the same period last year on +10.5% higher revenues, with 66.7% beating EPS estimates and 53.3% beating revenue estimates.Here is how the 2022 Q3 earnings and revenue growth rates for these 15 companies compares across different periods.Image Source: Zacks Investment ResearchHere is how the 2022 Q3 EPS and revenue beats percentages for these 15 companies compare across different periods.Image Source: Zacks Investment ResearchWe are trying hard not to draw any conclusions here given how small the sample size of Q3 results are at this stage. But it’s hard to put a gloss on the fact that these 15 index members, some of whom are true bellwethers, struggled to beat consensus estimates.In fact, you can see above that the 2022 Q3 EPS and revenue beats percentages are tracking the 5-year lows for this group of companies. Needless to add, it is hardly a reassuring start to the Q3 reporting cycle.The Earnings Big PictureTo get a sense of what is currently expected, take a look at the chart below that shows current earnings and revenue growth expectations for the S&P 500 index for 2022 Q3 and the following three quarters.Image Source: Zacks Investment ResearchAs you can see here, 2022 Q3 earnings are expected to be up +0.9% on +9.1% higher revenues.Don’t forget that it is the strong contribution from the Energy sector that is keeping the aggregate Q3 earnings growth in positive territory. Excluding the Energy sector, Q3 earnings for the rest of the S&P 500 index would be down -5.8% from the same period last year.Analysts have been lowering their estimates since the quarter got underway, as the chart below shows.Image Source: Zacks Investment ResearchThe -5.8% decline expected in Q3 on an ex-Energy basis is down from +2.1% in early July.Third quarter estimates have come down for all sectors, except Energy and Autos, with the biggest declines within Consumer Discretionary, Basic Materials, Consumer Staples, Technology, and Construction.In the aggregate, 2022 Q3 earnings estimates for the S&P 500 index have been cut -6.5% since mid-June. If we look at the revisions trend after excluding the Energy sector where estimates are still going up, aggregate Q3 estimates have declined by -8.5% since mid-June.Estimates for 2022 Q4 and full-year 2024 have also been coming down.These aren’t modest cuts to estimates, but rather towards the higher end of the historical range. The key takeaway here is that estimates have already been coming down. Yes, there may be some more cuts ahead, as we can reasonably expect will happen with estimates for Nike and Micron in the days ahead.But to suggest that earnings estimates have to massively come down to reach a ‘fair’ level would imply that we are projecting a global financial crisis type of economic event on the horizon, which is hard to justify given current economic fundamentals. We should also keep in mind that corporate earnings and revenues are in ‘nominal’ (or not adjusted for inflation) dollars and will largely keep pace with inflationary trends.The chart below shows the comparable picture on an annual basis.Image Source: Zacks Investment ResearchThe +6.8% earnings growth expected for the index this year drops to +0.3% once the Energy sector’s contribution is excluded.The chart below shows how the aggregate bottom-up earnings total for 2023 on an ex-Energy basis has evolved lately.Image Source: Zacks Investment ResearchFor a detailed look at the overall earnings picture, including expectations for the coming periods, please check out our weekly Earnings Trends report >>>>Are Earnings Estimates Out of Sync with the Economy?  This Little-Known Semiconductor Stock Could Be Your Portfolio’s Hedge Against Inflation Everyone uses semiconductors. But only a small number of people know what they are and what they do. If you use a smartphone, computer, microwave, digital camera or refrigerator (and that’s just the tip of the iceberg), you have a need for semiconductors. That’s why their importance can’t be overstated and their disruption in the supply chain has such a global effect. But every cloud has a silver lining. Shockwaves to the international supply chain from the global pandemic have unearthed a tremendous opportunity for investors. And today, Zacks' leading stock strategist is revealing the one semiconductor stock that stands to gain the most in a new FREE report. It's yours at no cost and with no obligation.>>Yes, I Want to Help Protect My Portfolio During the RecessionWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report NIKE, Inc. (NKE): Free Stock Analysis Report Micron Technology, Inc. (MU): Free Stock Analysis Report Conagra Brands (CAG): Free Stock Analysis Report FedEx Corporation (FDX): Free Stock Analysis Report Constellation Brands Inc (STZ): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: ZACKS5 hr. 3 min. ago Related News

What"s Going On With Nike?

Yesterday, Nike reported Q1 results, and despite posting a double-beat, shares underwent adverse price action. Earnings reports are always a spectacle. Companies finally pull the curtain back, unveiling how their businesses have fared behind closed doors.Sometimes, the market’s reaction is less than desired.Yesterday, NIKE NKE reported Q1 results, and despite posting a double-beat, shares underwent adverse price action.NIKE designs, develops, and markets athletic footwear, apparel, equipment, and services for men, women, and children worldwide.It’s been a harsh road for NIKE shares so far in 2022, down close to 50% and widely underperforming the general market. This is shown in the chart below.Image Source: Zacks Investment ResearchIt raises a valid question: what didn’t investors like from the quarterly print? Let’s take a closer look.Q1 ResultsNIKE came out of the gate and reported EPS of $0.93, marginally beating out the Zacks Consensus EPS estimate of $0.91 by 2.2%.It represented the company’s ninth consecutive quarter exceeding Zacks Consensus EPS Estimate and a 20% Y/Y downtick.NIKE raked in roughly $12.7 billion throughout the quarter, good enough to exceed the Zacks Consensus Sales estimate of $12.3 billion by a respectable 3%, reflecting the fourth consecutive quarter of exceeding top-line estimates and a 4% Y/Y increase.The company’s gross margin decreased to roughly 44%, negatively impacted by increased freight and logistics costs, lower margins across its NIKE Direct business, and unfavorable developments within net foreign currency exchange rates.However, the company's overstocked inventory was the pinnacle of the report, and investors didn’t take it lightly.NIKE’s inventories came in at $9.7 billion, reflecting a massive 44% Y/Y uptick.Many retailers have felt the full pain of a supply chain crunch in 2022, and NIKE has been no exception – overstocked inventories were driven by elevated in-transit times from ongoing uncertainty within the supply chain.Further, the company took somewhat drastic measures to address excess inventory in North America, such as NIKE Direct markdowns and even wholesale actions.Still, Matthew Friend, EVP and CFO, remained optimistic, saying, “Our focus continues to be the consumer, as we take action to navigate near-term dynamics while expanding long-term structural benefits through our Consumer Direct Acceleration strategy.”Time To Buy?The company’s earnings outlook has fallen notably over the last 60 days and the previous seven. Analysts have been in full agreement.Image Source: Zacks Investment ResearchNIKE’s forward earnings multiple has fallen drastically amid the stretch of poor price action, with the 25.5X value sitting well beneath its five-year median of 32.4X.Still, the value represents a 41% premium relative to its Zacks Consumer Discretionary Sector, and NKE sports a Style Score of a D for Value.Image Source: Zacks Investment ResearchHowever, the company has shown a commitment to shareholders, with five dividend payout increases over the last five years and a substantial 11% five-year annualized dividend growth rate.NIKE’s annual dividend yield of 1.3% beats out its Zacks Sector average of 1.1% by a fair margin.Image Source: Zacks Investment ResearchBottom LineFollowing a double-beat in its quarterly print, Nike shares have tumbled, with sellers out in full force.An overstocked inventory was the central spook of the release, with supply-chain volatility playing spoilsport.However, Nike’s CFO remains optimistic, also saying, “Our strong start to FY23 highlights the depth and breadth of NIKE’s global portfolio, as we continue to manage through volatility.”So, down nearly 50% YTD, is it time to buy NIKE NKE shares?With ongoing supply chain volatility spawning dark fiscal clouds over the retailer, it’s challenging to paint a bullish near-term outlook, even with a solid dividend.Recent negative earnings estimate revisions reflect this unfavorable near-term outlook.Instead, it looks vital for investors to wait until the weather clears up and positive earnings estimate revisions start rolling in. This Little-Known Semiconductor Stock Could Be Your Portfolio’s Hedge Against Inflation Everyone uses semiconductors. But only a small number of people know what they are and what they do. If you use a smartphone, computer, microwave, digital camera or refrigerator (and that’s just the tip of the iceberg), you have a need for semiconductors. That’s why their importance can’t be overstated and their disruption in the supply chain has such a global effect. But every cloud has a silver lining. Shockwaves to the international supply chain from the global pandemic have unearthed a tremendous opportunity for investors. And today, Zacks' leading stock strategist is revealing the one semiconductor stock that stands to gain the most in a new FREE report. It's yours at no cost and with no obligation.>>Yes, I Want to Help Protect My Portfolio During the RecessionWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report NIKE, Inc. (NKE): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: ZACKS5 hr. 3 min. ago Related News

Should You Hold Discover Financial (DFS) Stock for Now?

Discover Financial's (DFS) digital transformation efforts are positioning the company for long-term growth. Discover Financial Services DFS is well poised to grow on the back of digital transformation efforts, global expansions, and higher travel and entertainment spending. Its solid cash flow generating ability also bodes well. However, rising costs can reduce its margin.Discover Financial — with a market cap of $25.6 billion — is a digital banking and payment services company. The company offers credit cards, personal, student and home loans, as well as deposit products. Based in Riverwoods, IL, DFS has a major global presence.Courtesy of solid prospects, this currently Zacks Rank #3 (Hold) stock is worth holding on to at the moment.Trend in EstimatesThe Zacks Consensus Estimate for Discover Financial’s 2022 earnings is pegged at $15.33 per share, which has witnessed two upward revisions in the past 30 days against one in the opposite direction. DFS’ earnings beat estimates in each of the last four quarters, the average being 7%.Discover Financial Services Price and EPS Surprise Discover Financial Services price-eps-surprise | Discover Financial Services QuoteFurthermore, the consensus mark for revenues is $12.9 billion for 2022, indicating a 6.9% rise from the year-ago reported figure.Key DriversDiscover Financial’s digital transformation efforts are praiseworthy. Besides using in-house resources, it frequently resorts to third-party vendors to pursue technology advancements related to cloud, telecommunications, hardware and operating systems. These digital transformation efforts seem to be necessary to stay abreast with the growing digital trend. It launched the new Advanced Analytics Resource Center (AARC@606) program, which is expected to strengthen Discover Financial’s data and analytics wing and boost in-house resources.Improving consumer spending, despite inflationary pressure, will buoy DFS’ payment metrics. With the coming holiday season, payment volumes are expected to go up, leading to increased revenues. A rising net interest income will also keep boosting its Digital Banking Segment results. Net interest income rose 14% year over year to $2,610 million in the second quarter on the back of improved average receivables and expanded net interest margin.Discover Financial’s strong cash flow generating abilities are major positives. In the trailing 12-month period, net cash from operations increased 4.8% to $6.3 billion. It came up with free cash flow of $6.1 billion during this period, indicating a 4.9% jump. Its cash flow enables it to take actions to boost shareholder value. In April 2022, the company increased its quarterly dividend by 20% to 60 cents per share. (Check DFS’ dividend history here.)The company’s return on equity (ROE) indicates its massive growth potential. Its trailing 12-month ROE of 36.4% compares favorably with the industry average of 19.8%. Its 2022 outlook instills investors’ confidence in the stock. DFS expects loan growth to be in the low teens, up from the prior estimate of high single digits.The average net charge-off rate is projected in the range of 1.9-2.1% compared with the prior outlook of 2.2-2.4%. The net interest margin is also estimated to witness improvement within 5-15 bps when compared with the first-quarter 2022 figure.Key ConcernsThere are a few factors that are impeding the stock’s growth lately.Increasing costs are eating into the company’s profits. To compete with other credit card issuers, attract and retain customers and increase card usage, it incurs a considerable amount of expenses. Throughout 2021, total operating expenses jumped 6% to $4,805 million. In the first half of 2022, the metric increased 2% year over year to $1.1 billion. Rising costs can affect its bottom line.The growing competition in the payments market can be troubling for the company. Emerging payment firms with significant growth potential are rapidly capturing markets. Nevertheless, we believe that a systematic and strategic plan of action will drive its long-term growth.Stocks to ConsiderSome better-ranked stocks in the broader finance space are CI Financial Corp. CIXX, Owl Rock Capital Corporation ORCC and Primis Financial Corp. FRST, each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.Based in Toronto, CI Financial is a leading asset management holding company. The Zacks Consensus Estimate for CIXX’s 2022 earnings has increased 1.2% in the past 60 days.Headquartered in New York, Owl Rock Capital is a business development company. The Zacks Consensus Estimate for ORCC’s 2022 earnings indicates a 6.4% year-over-year increase.Based in McLean, VA, Primis Financial offers multiple financial services to businesses and individuals. The Zacks Consensus Estimate for FRST’s 2022 earnings has improved 8.8% in the past 60 days. This Little-Known Semiconductor Stock Could Be Your Portfolio’s Hedge Against Inflation Everyone uses semiconductors. But only a small number of people know what they are and what they do. If you use a smartphone, computer, microwave, digital camera or refrigerator (and that’s just the tip of the iceberg), you have a need for semiconductors. That’s why their importance can’t be overstated and their disruption in the supply chain has such a global effect. But every cloud has a silver lining. Shockwaves to the international supply chain from the global pandemic have unearthed a tremendous opportunity for investors. And today, Zacks' leading stock strategist is revealing the one semiconductor stock that stands to gain the most in a new FREE report. It's yours at no cost and with no obligation.>>Yes, I Want to Help Protect My Portfolio During the RecessionWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Discover Financial Services (DFS): Free Stock Analysis Report Owl Rock Capital Corporation (ORCC): Free Stock Analysis Report Primis Financial Corp. (FRST): Free Stock Analysis Report CI Financial Corp. (CIXX): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: ZACKS5 hr. 19 min. ago Related News

Fox (FOXA) Adds Fox Weather to Fios TV & Amazon Freevee

Fox (FOXA) expands the distribution of Fox Weather to Fios TV and Amazon Freevee. Fox Corporation FOXA recently announced that its Fox Weather is now available on Fios TV and Amazon Freevee.Fox Weather will be available to all Fios TV subscribers on channel 113 (SD) and channel 613 (HD), and on Amazon Freevee, viewers can access Fox Weather, a free ad-supported television channel through the app, or within the "Live TV" tab through Prime Video.In a short span since its launch, Fox Weather has added several distribution partners including The Roku Channel, fuboTV, YouTubeTV, Amazon News, DIRECTV STREAM, Xumo, WOW! and Vidgo.The growing popularity and rapid expansion of Fox Weather have been beneficial for Fox News Media, which is its parent company.Fox Gains From Growth of Its Multiple Business UnitsFox News Channel (“FNC”) has been performing well as it once again closed August as the best-performing news brand for 18 consecutive months, reaching more than 2.9 billion total multiplatform minutes, 1.5 billion total multiplatform views and 77 million unique multiplatform visitors, per Comscore data.The Cable Network Programming segment, which generates 44% of Fox’s revenues, witnessed 7% year-over-year growth as affiliate and advertising fees increased.The increase in advertising revenues was primarily due to higher pricing at FOX News Media and an increase in the number of live events at the national sports networks.FNC has also been benefiting from Fox Nation as its original content like Duck Family Treasure, Sharon Osbourne: To Hell & Back, the upcoming Yellowstone: One-Fifty with Kevin Costner and a comedy show named A Roseanne Comedy Special, featuring Roseanne Barr, is gaining traction.Fox Nation has increased FNC’s subscriber base by approximately 80% in fiscal 2022. The conversion rate of trialists to paid subscribers has been high and retention rates were above industry averages.Fox’s growing user base is not only driven by Fox News but also Fox Business, which drove 151 million multiplatform views as of last month. Fox Business surpassed CNN Business and Comcast’s CMCSA MSNBC in multiplatform views for the fifth straight month.Comcast’s MSNBC lost 19% of its prime-time viewers in the first half of 2022. Per Nielsen data, its ratings have plummeted ever since The Rachel Maddow show shifted to a once-per-week format from four times per week.Fox’s investment in Flutter has benefited its sports business division as well. Together they entered into a national media and sports wagering partnership in the United States. The partnership offers the FOX Bet Super 6 national free-to-play game, which has generated a user base of more than 6 million registered accounts as of June 2022.What Lies Ahead for Fox?Fox’s shares have declined 14.8% year to date compared with the Zacks Consumer & Discretionary Sector, which fell 38.9%.However, Fox’s cable TV business faces a serious threat from OTT platforms due to cord-cutting and changing consumer preferences. This cord-cutting does not bode well for Fox.In fourth-quarter fiscal 2022, Cable Network Programming EBITDA decreased 6.8% year over year to $628 million. The EBITDA margin contracted 520 bps to 43%.Fox also faces competition for ad dollars, which forms its main source of revenue. This is intensified by offerings from tech giants like Meta Platform’s META Facebook, Twitter TWTR, Google, YouTube and Amazon, as they too have been fighting for ad dollars.Meta benefits from increasing mobile ad revenues and growing adoption of stories by advertisers across Instagram. Twitter’s initiatives to add features and focus on effectively tackling abuse issues are helping it to expand the monetized user base, thereby driving ad revenues.However, Fox, which currently has a Zacks Rank #3 (Hold), remains confident for fiscal 2023 as the financial tailwinds from Super Bowl 57, the early exit of Thursday Night Football, the momentum heading into November's midterm elections and the start of its next major distribution cycle are expected to deliver record revenues and EBITDA.You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.  This Little-Known Semiconductor Stock Could Be Your Portfolio’s Hedge Against Inflation Everyone uses semiconductors. But only a small number of people know what they are and what they do. If you use a smartphone, computer, microwave, digital camera or refrigerator (and that’s just the tip of the iceberg), you have a need for semiconductors. That’s why their importance can’t be overstated and their disruption in the supply chain has such a global effect. But every cloud has a silver lining. Shockwaves to the international supply chain from the global pandemic have unearthed a tremendous opportunity for investors. And today, Zacks' leading stock strategist is revealing the one semiconductor stock that stands to gain the most in a new FREE report. It's yours at no cost and with no obligation.>>Yes, I Want to Help Protect My Portfolio During the RecessionWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Comcast Corporation (CMCSA): Free Stock Analysis Report Fox Corporation (FOXA): Free Stock Analysis Report Twitter, Inc. (TWTR): Free Stock Analysis Report Meta Platforms, Inc. (META): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: ZACKS5 hr. 19 min. ago Related News

Looking for a Growth Stock? 3 Reasons Why Mettler-Toledo (MTD) is a Solid Choice

Mettler-Toledo (MTD) could produce exceptional returns because of its solid growth attributes. Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. But finding a great growth stock is not easy at all.By their very nature, these stocks carry above-average risk and volatility. Moreover, if a company's growth story is over or nearing its end, betting on it could lead to significant loss.However, the Zacks Growth Style Score (part of the Zacks Style Scores system), which looks beyond the traditional growth attributes to analyze a company's real growth prospects, makes it pretty easy to find cutting-edge growth stocks.Mettler-Toledo (MTD) is on the list of such stocks currently recommended by our proprietary system. In addition to a favorable Growth Score, it carries a top Zacks Rank.Studies have shown that stocks with the best growth features consistently outperform the market. And returns are even better for stocks that possess the combination of a Growth Score of A or B and a Zacks Rank #1 (Strong Buy) or 2 (Buy).Here are three of the most important factors that make the stock of this maker of precision instruments a great growth pick right now.Earnings GrowthArguably nothing is more important than earnings growth, as surging profit levels is what most investors are after. For growth investors, double-digit earnings growth is highly preferable, as it is often perceived as an indication of strong prospects (and stock price gains) for the company under consideration.While the historical EPS growth rate for Mettler-Toledo is 17.4%, investors should actually focus on the projected growth. The company's EPS is expected to grow 14.7% this year, crushing the industry average, which calls for EPS growth of -11.9%.Impressive Asset Utilization RatioAsset utilization ratio -- also known as sales-to-total-assets (S/TA) ratio -- is often overlooked by investors, but it is an important indicator in growth investing. This metric shows how efficiently a firm is utilizing its assets to generate sales.Right now, Mettler-Toledo has an S/TA ratio of 1.17, which means that the company gets $1.17 in sales for each dollar in assets. Comparing this to the industry average of 0.72, it can be said that the company is more efficient.In addition to efficiency in generating sales, sales growth plays an important role. And Mettler-Toledo is well positioned from a sales growth perspective too. The company's sales are expected to grow 5.7% this year versus the industry average of 0%.Promising Earnings Estimate RevisionsSuperiority of a stock in terms of the metrics outlined above can be further validated by looking at the trend in earnings estimate revisions. A positive trend is of course favorable here. Empirical research shows that there is a strong correlation between trends in earnings estimate revisions and near-term stock price movements.There have been upward revisions in current-year earnings estimates for Mettler-Toledo. The Zacks Consensus Estimate for the current year has surged 0.1% over the past month.Bottom LineMettler-Toledo has not only earned a Growth Score of B based on a number of factors, including the ones discussed above, but it also carries a Zacks Rank #2 because of the positive earnings estimate revisions.You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.This combination positions Mettler-Toledo well for outperformance, so growth investors may want to bet on it. This Little-Known Semiconductor Stock Could Be Your Portfolio’s Hedge Against Inflation Everyone uses semiconductors. But only a small number of people know what they are and what they do. If you use a smartphone, computer, microwave, digital camera or refrigerator (and that’s just the tip of the iceberg), you have a need for semiconductors. That’s why their importance can’t be overstated and their disruption in the supply chain has such a global effect. But every cloud has a silver lining. Shockwaves to the international supply chain from the global pandemic have unearthed a tremendous opportunity for investors. And today, Zacks' leading stock strategist is revealing the one semiconductor stock that stands to gain the most in a new FREE report. It's yours at no cost and with no obligation.>>Yes, I Want to Help Protect My Portfolio During the RecessionWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report MettlerToledo International, Inc. (MTD): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: ZACKS5 hr. 19 min. ago Related News

Looking for a Growth Stock? 3 Reasons Why Banco De Chile (BCH) is a Solid Choice

Banco De Chile (BCH) possesses solid growth attributes, which could help it handily outperform the market. Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. But finding a great growth stock is not easy at all.In addition to volatility, these stocks carry above-average risk by their very nature. Also, one could end up losing from a stock whose growth story is actually over or nearing its end.However, the Zacks Growth Style Score (part of the Zacks Style Scores system), which looks beyond the traditional growth attributes to analyze a company's real growth prospects, makes it pretty easy to find cutting-edge growth stocks.Our proprietary system currently recommends Banco De Chile (BCH) as one such stock. This company not only has a favorable Growth Score, but also carries a top Zacks Rank.Research shows that stocks carrying the best growth features consistently beat the market. And returns are even better for stocks that possess the combination of a Growth Score of A or B and a Zacks Rank #1 (Strong Buy) or 2 (Buy).While there are numerous reasons why the stock of this company is a great growth pick right now, we have highlighted three of the most important factors below:Earnings GrowthEarnings growth is arguably the most important factor, as stocks exhibiting exceptionally surging profit levels tend to attract the attention of most investors. For growth investors, double-digit earnings growth is highly preferable, as it is often perceived as an indication of strong prospects (and stock price gains) for the company under consideration.While the historical EPS growth rate for Banco De Chile is 4.5%, investors should actually focus on the projected growth. The company's EPS is expected to grow 13.9% this year, crushing the industry average, which calls for EPS growth of 2.3%.Cash Flow GrowthWhile cash is the lifeblood of any business, higher-than-average cash flow growth is more important and beneficial for growth-oriented companies than for mature companies. That's because, growth in cash flow enables these companies to expand their businesses without depending on expensive outside funds.Right now, year-over-year cash flow growth for Banco De Chile is 76.1%, which is higher than many of its peers. In fact, the rate compares to the industry average of 34.6%.While investors should actually consider the current cash flow growth, it's worth taking a look at the historical rate too for putting the current reading into proper perspective. The company's annualized cash flow growth rate has been 8.7% over the past 3-5 years versus the industry average of 6%.Promising Earnings Estimate RevisionsBeyond the metrics outlined above, investors should consider the trend in earnings estimate revisions. A positive trend is a plus here. Empirical research shows that there is a strong correlation between trends in earnings estimate revisions and near-term stock price movements.The current-year earnings estimates for Banco De Chile have been revising upward. The Zacks Consensus Estimate for the current year has surged 3.6% over the past month.Bottom LineBanco De Chile has not only earned a Growth Score of A based on a number of factors, including the ones discussed above, but it also carries a Zacks Rank #2 because of the positive earnings estimate revisions.You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.This combination indicates that Banco De Chile is a potential outperformer and a solid choice for growth investors. This Little-Known Semiconductor Stock Could Be Your Portfolio’s Hedge Against Inflation Everyone uses semiconductors. But only a small number of people know what they are and what they do. If you use a smartphone, computer, microwave, digital camera or refrigerator (and that’s just the tip of the iceberg), you have a need for semiconductors. That’s why their importance can’t be overstated and their disruption in the supply chain has such a global effect. But every cloud has a silver lining. Shockwaves to the international supply chain from the global pandemic have unearthed a tremendous opportunity for investors. And today, Zacks' leading stock strategist is revealing the one semiconductor stock that stands to gain the most in a new FREE report. It's yours at no cost and with no obligation.>>Yes, I Want to Help Protect My Portfolio During the RecessionWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Banco De Chile (BCH): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: ZACKS5 hr. 19 min. ago Related News

Looking for a Growth Stock? 3 Reasons Why P.A.M. Transportation (PTSI) is a Solid Choice

P.A.M. Transportation (PTSI) is well positioned to outperform the market, as it exhibits above-average growth in financials. Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. But finding a great growth stock is not easy at all.By their very nature, these stocks carry above-average risk and volatility. Moreover, if a company's growth story is over or nearing its end, betting on it could lead to significant loss.However, the Zacks Growth Style Score (part of the Zacks Style Scores system), which looks beyond the traditional growth attributes to analyze a company's real growth prospects, makes it pretty easy to find cutting-edge growth stocks.Our proprietary system currently recommends P.A.M. Transportation (PTSI) as one such stock. This company not only has a favorable Growth Score, but also carries a top Zacks Rank.Research shows that stocks carrying the best growth features consistently beat the market. And returns are even better for stocks that possess the combination of a Growth Score of A or B and a Zacks Rank #1 (Strong Buy) or 2 (Buy).While there are numerous reasons why the stock of this trucking company is a great growth pick right now, we have highlighted three of the most important factors below:Earnings GrowthEarnings growth is arguably the most important factor, as stocks exhibiting exceptionally surging profit levels tend to attract the attention of most investors. And for growth investors, double-digit earnings growth is definitely preferable, and often an indication of strong prospects (and stock price gains) for the company under consideration.While the historical EPS growth rate for P.A.M. Transportation is 56.2%, investors should actually focus on the projected growth. The company's EPS is expected to grow 41.8% this year, crushing the industry average, which calls for EPS growth of 40.2%.Cash Flow GrowthWhile cash is the lifeblood of any business, higher-than-average cash flow growth is more important and beneficial for growth-oriented companies than for mature companies. That's because, growth in cash flow enables these companies to expand their businesses without depending on expensive outside funds.Right now, year-over-year cash flow growth for P.A.M. Transportation is 77.2%, which is higher than many of its peers. In fact, the rate compares to the industry average of 38.6%.While investors should actually consider the current cash flow growth, it's worth taking a look at the historical rate too for putting the current reading into proper perspective. The company's annualized cash flow growth rate has been 22% over the past 3-5 years versus the industry average of 11.7%.Promising Earnings Estimate RevisionsBeyond the metrics outlined above, investors should consider the trend in earnings estimate revisions. A positive trend is a plus here. Empirical research shows that there is a strong correlation between trends in earnings estimate revisions and near-term stock price movements.The current-year earnings estimates for P.A.M. Transportation have been revising upward. The Zacks Consensus Estimate for the current year has surged 11.1% over the past month.Bottom LineWhile the overall earnings estimate revisions have made P.A.M. Transportation a Zacks Rank #1 stock, it has earned itself a Growth Score of A based on a number of factors, including the ones discussed above.You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.This combination indicates that P.A.M. Transportation is a potential outperformer and a solid choice for growth investors. This Little-Known Semiconductor Stock Could Be Your Portfolio’s Hedge Against Inflation Everyone uses semiconductors. But only a small number of people know what they are and what they do. If you use a smartphone, computer, microwave, digital camera or refrigerator (and that’s just the tip of the iceberg), you have a need for semiconductors. That’s why their importance can’t be overstated and their disruption in the supply chain has such a global effect. But every cloud has a silver lining. Shockwaves to the international supply chain from the global pandemic have unearthed a tremendous opportunity for investors. And today, Zacks' leading stock strategist is revealing the one semiconductor stock that stands to gain the most in a new FREE report. It's yours at no cost and with no obligation.>>Yes, I Want to Help Protect My Portfolio During the RecessionWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report P.A.M. Transportation Services, Inc. (PTSI): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: ZACKS5 hr. 19 min. ago Related News

5 Winning Global ETFs of First Nine Months of 2022

These global fared better than the broader market indexes in the first nine months of 2022. Global markets have been into a tailspin this year on red-hot inflation and rising rate worries. The Fed has hiked interest rates this year by 300 bps so far. The European Central Bank (ECB) too embarked on the rate hike mode. The ECB has raised interest rates by 125 so far this year (read: ECB Hikes Rates: ETFs to Win/Lose).The Bank of England hiked its key interest rate to 2.25% from 1.75% on Thursday and said it would continue to "respond forcefully, as necessary" to tame inflation, despite the economic concerns.The Central Bank of Sweden announced a 100 basis points hike in interest rates last week saying that the inflation was too stubborn. Despite the 100-bps hike, the Riksbank is still behind its inflation target by 0.25%, which indicates further rate hikes. The Swiss central bank also hiked rates by 75 basis points to 0.5% Thursday. The move brought an end to an era of negative rates in Europe.The S&P 500 is down about 22% this year (as of Sep 23, 2022) while iShares MSCI ACWI ETF ACWI has added about 23.9% this year. Against this backdrop, below we highlight a few global equities ETFs that outdid the S&P 500 this year.ETFs in FocusWBI BullBear Yield 3000 ETF WBIG – Down 5.79% YTDThe WBI BullBear Yield 3000 ETF seeks long-term capital appreciation and the potential for current income, while also seeking to protect principal during unfavorable market conditions. This active cash-hedged all-cap ETF focused on value stocks with attractive dividend yields. The fund holds 60.9% of stock and 39.1% of cash. The expense ratio of WBIG is 1.25% while it yields 2.42% annually.WBI BullBear Yield 3000 ETF (WBIF) – Down 7.76% YTDWBIF is an active ETF focused on global small-, mid- and large-cap value stocks that pay dividends. The fund seeks to manage risk to capital while providing attractive returns and long-term growth of capital. The rigorous stock selection process targets the highest quality value stocks. The expense ratio of WBIG is 1.25% and it yields 1.52% annually.Alpha Architect Value Momentum Trend ETF VMOT – Down 9.6% YTDThe Alpha Architect Value Momentum Trend ETF seeks long term capital appreciation while attempting to minimize market drawdowns. The strategy seeks to invest in the cheapest, highest quality value stocks that have the highest quality momentum too. The strategy’s trend-following system looks to minimize large drawdowns via trend signals. The fund charges 83 bps in fees.Horizon Kinetics Inflation Beneficiaries ETF INFL – Down 10.7% YTDThe Horizon Kinetics Inflation Beneficiaries ETF is an actively managed ETF that seeks long-term growth of capital in real (inflation-adjusted) terms. It seeks to achieve its investment objective by investing primarily in domestic and foreign equity securities of companies that are expected to benefit, either directly or indirectly, from rising prices of real assets, such as those whose revenues are expected to increase with inflation without corresponding increases in expenses. The fund charges 85 bps in fees.IQ Hedge Macro Tracker ETF MCRO – Down 11.3% YTDThe underlying IQ Hedge Macro Index seeks to replicate the risk-adjusted return characteristics of a combination of hedge funds pursuing a macro strategy and hedge funds pursuing an emerging markets strategy. The fund charges 67 bps in fees. Want key ETF info delivered straight to your inbox? Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week.Get it free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report iShares MSCI ACWI ETF (ACWI): ETF Research Reports Alpha Architect Value Momentum Trend ETF (VMOT): ETF Research Reports WBI BullBear Yield 3000 ETF (WBIG): ETF Research Reports IQ Hedge Macro Tracker ETF (MCRO): ETF Research Reports Horizon Kinetics Inflation Beneficiaries ETF (INFL): ETF Research Reports To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: ZACKS5 hr. 19 min. ago Related News

Biohaven Pharma"s (BHVN) ALS Study Fail to Meet Both Endpoints

Biohaven Pharmaceuticals (BHVN) suffers a setback as verdiperstat fails to meet the primary and secondary endpoints in an ALS study. Biohaven Pharmaceuticals BHVN recently announced that the phase II/III HEALY ALS platform study evaluating verdiperstat for treating Amyotrophic Lateral Sclerosis (ALS) failed.ALS is a progressive, rare and life-threatening neuromuscular disease characterized by the loss of motor neurons in the brain, brainstem, and spinal cord that leads to progressive muscle weakness and difficulties in speaking, swallowing, and breathing. Per the company, the disease affects approximately 30,000 people in the United States. Presently, there are no approved treatment options and no cure for ALS.The HEALY ALS study is an adaptive study evaluating multiple investigational treatments simultaneously for the easy and accelerated development of treatment options for ALS patients.Biohaven evaluated verdiperstat in the study participants with ALS for a period of 24 weeks. The candidate did not exhibit any statistically significant difference in the prescribed primary efficacy outcome, disease progression measured by the ALS Functional Rating Scale-Revised or survival in patients who received the drug compared with a placebo. The candidate also did not exhibit any improvements in the key secondary efficacy measures of the study.The initial data from the safety analysis of the study was in line with the candidate’s previous studies.The company continues to conduct additional analyses of the candidate and expects to report results from the complete results at an upcoming scientific meeting.Shares of Biohaven have returned 9.9% in the year-to-date period against the industry’s decline of 24.5%.Image Source: Zacks Investment ResearchBiohaven is a commercial-stage biopharma company focused on developing and commercializing therapies for rare neurological and neuropsychiatric diseases.Biohaven is also conducting a phase III study evaluating taldefgrobep alfa in Spinal Muscle Atrophy (SMA). In July, the company initiated the enrollment of participants in the SMA phase III study.Biohaven is among a handful of companies exploring the ALS market. Notably, in the ALS space, there are two companies, namely Amylyx Pharmaceuticals AMLX andIonis Pharmaceuticals IONS, who have made progress in the target market.Amylyx Pharmaceuticals recently announced that the FDA approved its pipeline candidate, Relyvrio (sodium phenylbutyrate and taurursodiol), for treating ALS in adults. In a randomized placebo-controlled study, Relyvrio significantly slowed down the loss of physical function in adult ALS patients.Ionis is also developing several candidates for different forms of ALS, including ION363 for ALS, with mutations in the fused in sarcoma gene, or FUS (FUS-ALS), and tofersen, in partnership with Biogen, for superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS)In July, the FDA accepted the new drug application (NDA) for Ionis/Biogen’s tofersen in the treatment of SOD1-ALS. The application has also been granted priority review and a decision is expected by Jan. 25, 2023.Biohaven Pharmaceutical Holding Company Ltd. Price  Biohaven Pharmaceutical Holding Company Ltd. price | Biohaven Pharmaceutical Holding Company Ltd. Quote Investors should note that Biohaven entered into a definitive contract with Pfizer PFE in May 2022, wherein the latter will acquire the former for an all-cash transaction of $148.50 per share or a total equity value of $11.6 million.Per the terms of the transaction, Pfizer will acquire Biohaven’s calcitonin gene-related peptide (CGRP) pipeline. With regard to the non-CGRP pipeline, all existing shareholders of Biohaven (including Pfizer) will receive half a share of a new publicly traded company that will retain the company’s non-CGRP programs for every one common share of Biohaven. The new company will continue to operate under Biohaven’s name. The transaction is expected to be complete by early 2023.Biohaven currently has a Zacks Rank #3 (Hold).You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here. This Little-Known Semiconductor Stock Could Be Your Portfolio’s Hedge Against Inflation Everyone uses semiconductors. But only a small number of people know what they are and what they do. If you use a smartphone, computer, microwave, digital camera or refrigerator (and that’s just the tip of the iceberg), you have a need for semiconductors. That’s why their importance can’t be overstated and their disruption in the supply chain has such a global effect. But every cloud has a silver lining. Shockwaves to the international supply chain from the global pandemic have unearthed a tremendous opportunity for investors. And today, Zacks' leading stock strategist is revealing the one semiconductor stock that stands to gain the most in a new FREE report. It's yours at no cost and with no obligation.>>Yes, I Want to Help Protect My Portfolio During the RecessionWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report Ionis Pharmaceuticals, Inc. (IONS): Free Stock Analysis Report Biohaven Pharmaceutical Holding Company Ltd. (BHVN): Free Stock Analysis Report Amylyx Pharmaceuticals, Inc. (AMLX): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: ZACKS5 hr. 19 min. ago Related News

Top Analyst Reports for Novo Nordisk, Suncor Energy, & Nasdaq

Today's Research Daily features new research reports on 12 major stocks, including Novo Nordisk A/S (NVO), Suncor Energy Inc. (SU) and Nasdaq, Inc. (NDAQ). Friday, September 30, 2022 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 12 major stocks, including Novo Nordisk A/S (NVO), Suncor Energy Inc. (SU) and Nasdaq, Inc. (NDAQ). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today. You can see all of today’s research reports here >>> Novo Nordisk shares have underperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+4.7% vs. +7.1%). The Zacks analyst believes that lower realized prices in the United States, loss of exclusivity for products and stiff competition are affecting company’s sales. Sales are also being negatively impacted by the COVID-19 pandemic. The supply challenges for Wegovy have impacted the stock. The patent expiry on some of the products in Novo Nordisk’s portfolio remains a woe. However, the promising diabetes drug, Ozempic, is off to a solid start since its launch. The drug remains the growth engine for the company. The launch of Rybelsus also looks impressive. Novo Nordisk has one of the broadest diabetes portfolios in the industry. Drug sales have been gaining and maintaining momentum. (You can read the full research report on Novo Nordisk here >>>) Suncor Energy’s shares have advanced +35.1% over the past year against the Zacks Oil and Gas - Integrated - Canadian industry’s gain of +42.8%. The Zacks analyst believes that the company has an impressive supply chain network, owning significant oil sands and conventional production platforms, along with a strong downstream portfolio. Suncor Energy is one of the best positioned companies in the energy space given its access to abundant resources, rich operating experience and technical know-how. Suncor Energy's major projects, including Fort Hills and Syncrude, should support its growth momentum. The company's strong liquidity and modest near-term debt maturities are other positives. Moreover, Suncor Energy plans to maintain a disciplined capital approach and estimates to repay further debt in 2022, thereby indicating its ability to generate cash flow. (You can read the full research report on Suncor Energy here >>>) Nasdaq shares have outperformed the Zacks Securities and Exchanges industry over the past three-month period (+10.1% vs. -4.4%). The Zacks analyst believes that the company has been successful in maximizing opportunities as a technology and analytics provider and growing core marketplace businesses. Focus on growth via acquisitions and organic initiatives, which aided its entry into new markets and helped it gain cross-selling opportunities, bodes well. Intense focus on Market Technology and Information Services businesses also helps the company to explore vast opportunities per its developmental strategies. Nasdaq remains committed to deploy capital effectively by investing in organic growth initiatives. Its board announced a three-for-one stock split in the form of a stock dividend. However, high expenses weigh on margin expansion. High leverage ratio poses risk. (You can read the full research report on Nasdaq here >>>) Other noteworthy reports we are featuring today include W.W. Grainger, Inc. (GWW), Textron Inc. (TXT), and Magnolia Oil & Gas Corporation (MGY). Sheraz Mian Director of Research Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must ReadNovo Nordisk's (NVO) Diabetes Drugs Aid Growth Amid RivalrySuncor (SU) Buoyed by Integrated Business ModelAccelerating Non-Trading Revenue Base Aids Nasdaq (NDAQ)Featured ReportsInnovations to Aid Textron (TXT), Supply Shortage May HurtPer the Zacks analyst, new product launch will enable Textron to capture more shares in the market. Yet COVID-19 induced global supply chain shortage might hurt deliveries and thereby its revenues.High-Quality Eagle Ford Acreage to Aid Magnolia (MGY)The Zacks analyst likes Magnolia Oil and Gas' high-quality acreage in the Eagle Ford shale but is worried over the absence of any hedge protection to tackle commodity price volatility.International Operations Aid FTI Consulting (FCN), Cost HighPer the Zacks analyst, FTI Consulting's strong international operations make it an excellent partner for global clients, generating continued revenue growth. Rising investment costs is a concern.Defense Wins Aid Oshkosh (OSK) Amid Cost InflationProgram wins like USPS, NGDC, MCWS in the Defense segment drive long-run growth for Oshkosh. However, per the Zacks analyst, soaring costs of material and freight decrease manufacturing efficiency.Blackberry (BB) To Benefit From Strong Product PortfolioPer the Zacks analyst, Blackberry's performance benefitted from strong revenue growth across all business segments. However, pandemic-related supply-chain issues remain concerns.New UpgradesStrong Demand, Growth in E-Commerce Sales Aid Grainger (GWW)Per the Zacks analyst, Grainger is poised well to gain on strong demand in its end markets and efforts to strengthen customer relationships and investment in e-commerce and digital capabilities.Higher Jet Engine Product Demand, Transformation Drive ATIPer the Zacks analyst, higher demand for jet engine products will drive results in ATI's HPMC segment. It will also gain from actions to improve cost structure through transformation efforts.New DowngradesLow Volumes in Tools & Outdoor Unit Hurt Stanley Black (SWK)The Zacks analyst is concerned about volume softness in the Tools & Outdoor segment due to reduced consumer spending as a result of an increase in interest rates and a spike in fuel prices.Low Iron Ore Prices & High Costs Hurt National Steel (SID)The Zacks analyst is concerned that the recent downtrend in iron ore prices and higher costs for raw materials and fuel rising cost will weigh on National Steel's margins. This Little-Known Semiconductor Stock Could Be Your Portfolio’s Hedge Against Inflation Everyone uses semiconductors. But only a small number of people know what they are and what they do. If you use a smartphone, computer, microwave, digital camera or refrigerator (and that’s just the tip of the iceberg), you have a need for semiconductors. That’s why their importance can’t be overstated and their disruption in the supply chain has such a global effect. But every cloud has a silver lining. Shockwaves to the international supply chain from the global pandemic have unearthed a tremendous opportunity for investors. And today, Zacks' leading stock strategist is revealing the one semiconductor stock that stands to gain the most in a new FREE report. It's yours at no cost and with no obligation.>>Yes, I Want to Help Protect My Portfolio During the RecessionWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Textron Inc. (TXT): Free Stock Analysis Report Nasdaq, Inc. (NDAQ): Free Stock Analysis Report Novo Nordisk AS (NVO): Free Stock Analysis Report Suncor Energy Inc. (SU): Free Stock Analysis Report W.W. Grainger, Inc. (GWW): Free Stock Analysis Report Magnolia Oil & Gas Corp (MGY): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: ZACKS5 hr. 19 min. ago Related News

Carnival (CCL) Q3 Earnings & Revenues Lag Estimates, Rise Y/Y

Carnival's (CCL) third-quarter fiscal 2022 performance reflects solid booking trends owing to relaxed protocols and better alignment of land-based vacation alternatives. Carnival Corporation & plc CCL reported third-quarter fiscal 2022 (ended Aug 31, 2022) results, with earnings and revenues missing the Zacks Consensus Estimate. Both the metrics lagged the consensus mark for the eighth straight quarter. Nevertheless, the top and the bottom line improved on a year-over-year basis.Carnival Corporation's chief executive officer Josh Weinstein, stated, "During our third quarter our business continued its positive trajectory, achieving over $300 million of adjusted EBITDA and reaching nearly 90% occupancy on our August sailings. We are continuing to close the gap to 2019 as we progress through the year, building occupancy on higher capacity and lower unit costs."Earnings & RevenuesIn the quarter under review, the company reported a loss per share of 58 cents, wider than the Zacks Consensus Estimate of a loss of 12 cents. In the year-ago quarter, the company had reported a loss per share of $1.75.Carnival Corporation Price, Consensus and EPS Surprise  Carnival Corporation price-consensus-eps-surprise-chart | Carnival Corporation Quote Revenues in the quarter totaled $4,305 million, which fell short of the consensus mark of $4,951 million. The top line improved sharply from the prior-year quarter’s figure of $546 million. Passenger ticket and onboard and other revenues were $2,595 million and $1,711 million, respectively.Q3 FinancialsDuring the fiscal third quarter, the company reported an adjusted net loss of $688 million. GAAP net loss for the quarter amounted to $770 million.In third-quarter fiscal 2022, occupancy came in at 84% compared with 69% reported in the prior quarter. Available lower berth days (“ALBD”) in the quarter were 21 million, marking 92% of total fleet capacity, up from 74% in second-quarter fiscal 2022.For cruise segments, revenue per PCD for the third quarter of fiscal 2022 declined from strong 2019 levels.Balance SheetCash, cash equivalents and short-term investments as of Aug 31, 2022, were $7.1 billion compared with $7.2 billion in the prior quarter. Carnival ended the quarter with liquidity of $7.4 billion. Total debt (current and long-term) as of Aug 31, 2022, was $34.1 billion compared with $35.1 billion as of May 31, 2022.Adjusted EBITDA, as of Aug 31, 2022, came in at $303 against $(928) reported in the previous quarter.Bookings UpdateDuring the fiscal third quarter, the company reported accelerated booking volumes on account of relaxed protocols and better alignment of land-based vacation alternatives. Cumulative advance bookings for the fourth quarter of fiscal 2022 are below the historical range. The company stated that cumulative advanced bookings for the first half of 2023 are above the historical ranges and at increased prices compared with 2019 levels.Meanwhile, total customer deposits as of Aug 31 were $4.8 billion compared with $5.1 billion as of May 31, 2022. As of Sep 30, 2022, 95% of the company's capacity had resumed guest cruise operations.GuidanceThe company continues to expect a net loss for the fourth quarter of fiscal 2022. Given the ongoing resumption of guest cruise operations, the company anticipates continued improvement in adjusted EBITDA and occupancy during 2023. It expects eight of its nine brands to have their entire fleet operational by the fourth quarter of fiscal 2022.Zacks Rank and Stocks to ConsiderCurrently, Carnival carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.Some better-ranked stocks in the Zacks Consumer Discretionary sector include Marriott Vacations Worldwide Corporation VAC, Hyatt Hotels Corporation H and Choice Hotels International, Inc. CHH.Marriott Vacations sports a Zacks Rank #1. VAC has a trailing four-quarter earnings surprise of 13.9%, on average. The stock has declined 24.9% in the past year.The Zacks Consensus Estimate for VAC’s current financial year sales and EPS indicates an increase of 19.7% and 131.4%, respectively, from the year-ago period’s reported levels.Hyatt carries a Zacks Rank #2. H has a trailing four-quarter earnings surprise of 798.8%, on average. The stock has declined 0.6% in the past year.The Zacks Consensus Estimate for H’s current financial year sales and EPS indicates growth of 89.1% and 113%, respectively, from the year-ago period’s reported levels.Choice Hotels carries a Zacks Rank #2. CHH has a trailing four-quarter earnings surprise of 11.2%, on average. The stock has declined 17.4% in the past year.The Zacks Consensus Estimate for CHH’s current financial year sales and EPS indicates growth of 25.3% and 21.7%, respectively, from the year-ago period’s reported levels. This Little-Known Semiconductor Stock Could Be Your Portfolio’s Hedge Against Inflation Everyone uses semiconductors. But only a small number of people know what they are and what they do. If you use a smartphone, computer, microwave, digital camera or refrigerator (and that’s just the tip of the iceberg), you have a need for semiconductors. That’s why their importance can’t be overstated and their disruption in the supply chain has such a global effect. But every cloud has a silver lining. Shockwaves to the international supply chain from the global pandemic have unearthed a tremendous opportunity for investors. And today, Zacks' leading stock strategist is revealing the one semiconductor stock that stands to gain the most in a new FREE report. It's yours at no cost and with no obligation.>>Yes, I Want to Help Protect My Portfolio During the RecessionWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Carnival Corporation (CCL): Free Stock Analysis Report Hyatt Hotels Corporation (H): Free Stock Analysis Report Choice Hotels International, Inc. (CHH): Free Stock Analysis Report Marriot Vacations Worldwide Corporation (VAC): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: ZACKS5 hr. 19 min. ago Related News

RPM International (RPM) to Post High Q1 Earnings on Solid Pricing

RPM International's (RPM) fiscal first-quarter earnings to reflect strong pricing actions amid inflationary woes. RPM International Inc. RPM is slated to report first-quarter fiscal 2023 results (ended Aug 31) on Oct 5, before the opening bell.In the last reported quarter, the company’s earnings lagged the Zacks Consensus Estimate by 1.4%, but net sales marginally topped the same. On a year-over-year basis, earnings and net sales increased 10.9% and 13.7%, respectively.The Trend in Estimate RevisionThe Zacks Consensus Estimate for the to-be-reported quarter’s earnings has been unchanged at $1.33 per share over the past 60 days. The estimated value indicates a 23.2% increase from the year-ago earnings of $1.08 per share. The consensus mark for revenues is $1.89 billion, suggesting a 14.5% year-over-year improvement.RPM International Inc. Price and EPS Surprise RPM International Inc. price-eps-surprise | RPM International Inc. Quote Factors to ConsiderRPM’s fiscal first-quarter earnings and revenues are likely to have increased from the prior year’s levels on prudent cost management and solid pricing. Also, improvement in the construction and industrial maintenance activity, a rebound in energy markets and its focus on investments in the fastest-growing areas of its business are likely to have added to the positives.RPM International expects net sales to increase in the mid-teens. It also expects sales growth in the mid-teens across the operating segments. Particularly, the Consumer Group is likely to generate the highest growth of the four segments backed by selling price increases, improved alkyd resin supply and investments in operations.The Zacks Consensus Estimate for Construction Products Group or CPG net sales of $688 million suggests a 6.8% increase from a year ago. The same for Performance Coatings Group or PCG sales are likely to rise 6.8% to $305 million from the previous year’s levels.The consensus estimate for Consumer Group or CG net sales of $579 million suggests a 7.5% increase from a year ago. The same for Specialty Products Group or SPG sales are likely to increase 5.4% to $192 million from a year ago.RPM intends to increase prices for certain raw materials, labor and packaging to forgo unprecedented supply-chain and inflationary woes. Higher costs from unreliable bulk transportation (which creates production inefficiencies) and fuel surcharges (driven by high energy prices) are expected to have affected the CG segment. Also, it anticipates a strengthening U.S. dollar to remain a headwind for the fiscal first quarter.RPM anticipates the fiscal first quarter’s adjusted EBIT to increase 20-25% versus a fall of 23.2% reported in first-quarter fiscal 2022.The consensus mark for CPG’s adjusted EBIT is likely to increase 4.9% year over year. The same for PCG’s adjusted EBIT is likely to improve 8.9% from the prior year’s levels. The consensus estimate for CG’s adjusted EBIT is likely to rise 30.1% and that of SPG is likely to increase 21% from the prior year’s tally.What Our Model IndicatesOur proven model does not conclusively predict an earnings beat for RPM International this time around. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. Unfortunately, that is not the case here, as you will see below.Earnings ESP: Its earnings ESP is -1.26%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.Zacks Rank: The company currently has a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.Stocks With Favorable CombinationAccording to our model, here are some companies in the broader construction sector that have the right combination of elements to post an earnings beat in their respective quarters to be reported.Primoris Services Corporation PRIM has an Earnings ESP of +13.85% and a Zacks Rank #2.PRIM’s earnings topped the consensus mark in two of the last four quarters and missed the other two occasions, with the average being negative 19.6%. Earnings for the to-be-reported quarter are expected to grow 10.1% year over year.Dycom Industries, Inc. DY has an Earnings ESP of +2.34% and a Zacks Rank #1.DY’s earnings topped the consensus mark in all of the trailing four quarters, with the average surprise being 140%. Earnings for the to-be-reported quarter are expected to grow 34.7% year over year.Boise Cascade Company BCC has an Earnings ESP of +3.29% and a Zacks Rank #2.BCC’s earnings topped the consensus mark in all the last four quarters, with the average being 27.1%. Earnings for the to-be-reported quarter are expected to grow 92.6% year over year.Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar. This Little-Known Semiconductor Stock Could Be Your Portfolio’s Hedge Against Inflation Everyone uses semiconductors. But only a small number of people know what they are and what they do. If you use a smartphone, computer, microwave, digital camera or refrigerator (and that’s just the tip of the iceberg), you have a need for semiconductors. That’s why their importance can’t be overstated and their disruption in the supply chain has such a global effect. But every cloud has a silver lining. Shockwaves to the international supply chain from the global pandemic have unearthed a tremendous opportunity for investors. And today, Zacks' leading stock strategist is revealing the one semiconductor stock that stands to gain the most in a new FREE report. It's yours at no cost and with no obligation.>>Yes, I Want to Help Protect My Portfolio During the RecessionWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Dycom Industries, Inc. (DY): Free Stock Analysis Report Primoris Services Corporation (PRIM): Free Stock Analysis Report RPM International Inc. (RPM): Free Stock Analysis Report Boise Cascade, L.L.C. (BCC): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: ZACKS5 hr. 19 min. ago Related News

Sarepta (SRPT) Seeks FDA Nod for DMD Gene Therapy Candidate

If approved, Sarepta's (SRPT) SRP-9001 will be the first gene therapy for DMD indication in the United States. The company seeks approval for gene therapy under the accelerated pathway. Sarepta Therapeutics SRPT submitted a biologics license application (BLA) to the FDA seeking accelerated approval for its gene therapy candidate, SRP-9001, to treat ambulant patients with Duchenne muscular dystrophy (DMD). The therapy is being developed in partnership with Roche RHHBY.The BLA filing is supported by data from multiple studies from the clinical development program evaluating SRP-9001 in DMD. Earlier this June, Sarepta and Roche announced new functional data across these studies, demonstrating that treatment with SRP-9001 led to functional improvements in individuals suffering from DMD compared with a propensity-weighted external control group at multiple times. The time points vary from one-, two- and four years post-treatment.Management also initiated a pivotal phase III study, EMBARK, last year. It will act as a confirmatory study seeking full approval for SRP-9001 in DMD.Shares of Sarepta have risen 21.7% in the year-to-date period against the industry’s 25.2% decline.Image Source: Zacks Investment ResearchIf approved by the FDA, SRP-9001 will be the first gene therapy available for DMD patients. The therapy is also expected to generate a billion dollars in revenue for Sarepta. The gene therapy has been granted Fast Track, Rare Pediatric Disease (RPD) and orphan drug designations by the FDA.Sarepta and Roche entered into a licensing agreement in 2019 to develop SRP-9001 for DMD. Per the agreement, Roche has exclusive rights to launch and commercialize SRP-9001 in ex-U.S. markets.Apart from SRP-9001, the company is also developing SRP-5051 (vesleteplirsen), its next-generation exon-skipping pipeline candidate for treating DMD patients with skipping exon 51.Earlier this month, the FDA removed a clinical hold on clinical studies evaluating SRP-5051. As part of the condition for removing the clinical hold, Sarepta will modify the global protocols for clinical studies evaluating SRP-5051 to include expanded monitoring of urine biomarkers.Sarepta’s commercial portfolio consists of three RNA-based PMO therapies, targeting DMD — Exondys 51, Vyondys 53 and Amondys 45. These drugs can potentially address nearly a third of all patients with DMD in the United States.Sarepta Therapeutics, Inc. Price  Sarepta Therapeutics, Inc. price | Sarepta Therapeutics, Inc. Quote Zacks Rank & Stocks to ConsiderSarepta currently carries a Zacks Rank #4 (Sell). Some better-ranked stocks in the overall healthcare sector include Morphic MORF and Sanofi SNY. While Morphic sports a Zacks Rank #1 (Strong Buy) at present, Sanofi carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.In the past 60 days, estimates for Morphic’s 2022 loss per share have narrowed from $3.38 to $1.80. Loss estimates for 2023 have narrowed from $3.91 to $3.62 during the same period. Shares of Morphic have lost 40.9% in the year-to-date period.Earnings of Morphic beat estimates in three of the last four quarters and missed the mark just once, witnessing a surprise of 48.29%, on average. In the last reported quarter, MORF delivered an earnings surprise of 183.95%.In the past 60 days, estimates for Sanofi’s 2022 earnings per share have increased from $4.08 to $4.14. Earnings estimates for 2023 have increased from $4.25 to $4.29 during the same period. Shares of Sanofi have lost 24.2% in the year-to-date period.Earnings of Sanofi beat estimates in each of the last four quarters, witnessing a surprise of 9.37%, on average. In the last reported quarter, SNY delivered an earnings surprise of 8.24%. This Little-Known Semiconductor Stock Could Be Your Portfolio’s Hedge Against Inflation Everyone uses semiconductors. But only a small number of people know what they are and what they do. If you use a smartphone, computer, microwave, digital camera or refrigerator (and that’s just the tip of the iceberg), you have a need for semiconductors. That’s why their importance can’t be overstated and their disruption in the supply chain has such a global effect. But every cloud has a silver lining. Shockwaves to the international supply chain from the global pandemic have unearthed a tremendous opportunity for investors. And today, Zacks' leading stock strategist is revealing the one semiconductor stock that stands to gain the most in a new FREE report. It's yours at no cost and with no obligation.>>Yes, I Want to Help Protect My Portfolio During the RecessionWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Sanofi (SNY): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report Sarepta Therapeutics, Inc. (SRPT): Free Stock Analysis Report Morphic Holding, Inc. (MORF): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: ZACKS5 hr. 19 min. ago Related News

BioMarin (BMRN) Refiles BLA With FDA for Hemophilia Gene Therapy

If approved, BioMarin's (BMRN) valoctocogene roxaparvovec will be the first gene therapy for hemophilia A in the United States. The FDA filing also incorporates BMRN's responses to the CRL issued to the BLA in 2020. BioMarin Pharmaceutical Inc. BMRN resubmitted the biologics license application (BLA) to the FDA, seeking approval for valoctocogene roxaparvovec (valrox) gene therapy to treat adult patients with severe hemophilia A.BioMarin had previously submitted a BLA in 2019 for valrox to address hemophilia A. However, the FDA issued a complete response letter (CRL) to the BLA ahead of the PDUFA date in August 2020. This was due to the regulatory agency’s dissatisfaction with the available data. As a result, it asked for two-year follow-up information on the annualized bleed rates from the GENEr8-1 study only to provide additional evidence of a durable effect.The refiled BLA is based on two-year outcomes data from the phase III study, GENEr8-1, evaluating Roctavian in patients with hemophilia A. Data from the GENEr8-1 study showed that treatment with valrox led to stable and durable bleed control. Participants who were treated with the therapy achieved significantly reduced annualized bleeding rate and the mean annualized factor VIII (a blood clotting protein) infusion rate. Treatment with gene therapy also demonstrated superiority to the current standard of care, Factor VIII prophylactic therapy.While resubmissions to the FDA are followed by a six-month review procedure, BioMarin also expects to submit additional data to strengthen its BLA filing. Based on these data submissions, management expects the review procedure to extend by three months.Shares of BioMarin have fallen 3.7% in the year-to-date period compared to the industry’s 25.2% decline.Image Source: Zacks Investment ResearchA one-time infusion, valrox is designed to enable the body to produce Factor VIII on its own. Moreover, the patients are also not required to be administered a continued hemophilia prophylaxis, which in other marketed therapies is required.If valrox is approved by the FDA, it will be the first gene therapy in the United States for hemophilia A. The gene therapy has been granted Regenerative Medicine Advanced Therapy (RMAT), Breakthrough Therapy and orphan drug designations by the FDA.Last month, the European Commission (EC) granted conditional approval to valrox for treating adult patients with severe hemophilia A. The therapy is being marketed by BioMarin under the trade name Roctavian.Following the EC decision, Roctavian became the first approved gene therapy for hemophilia A in the European Union (EU). Per the EC, the use of Roctavian carries significant benefits over currently marketed therapies in treating hemophilia A. In fact, the EC has also endorsed the EMA’s recommendation and granted Roctavian orphan drug designation (ODD). Following the grant of ODD, the drug now has a 10-year market exclusivity in the EU.BioMarin Pharmaceutical Inc. Price  BioMarin Pharmaceutical Inc. price | BioMarin Pharmaceutical Inc. Quote Zacks Rank & Stocks to ConsiderBioMarin currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the overall healthcare sector include Morphic MORF, Sesen Bio SESN and Sanofi SNY. While Morphic and Sesen Bio sport a Zacks Rank #1 (Strong Buy) at present, Sanofi carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.In the past 60 days, estimates for Morphic’s 2022 loss per share have narrowed from $3.38 to $1.80. Loss estimates for 2023 have narrowed from $3.91 to $3.62 during the same period. Shares of Morphic have lost 40.9% in the year-to-date period.Earnings of Morphic beat estimates in three of the last four quarters and missed the mark just once, witnessing a surprise of 48.29%, on average. In the last reported quarter, MORF delivered an earnings surprise of 183.95%.Estimates for Sesen Bio’s 2023 bottom line have narrowed from 27 cents to 1 cent in the past 60 days. Share prices of Sesen Bio have fallen 52.2% in the year-to-date period.Earnings of Sesen Bio beat estimates in each of the last four quarters, the average surprise being 89.49%. In the last reported quarter, Sesen Bio delivered an earnings surprise of 61.54%.In the past 60 days, estimates for Sanofi’s 2022 earnings per share have increased from $4.08 to $4.14. Earnings estimates for 2023 have increased from $4.25 to $4.29 during the same period. Shares of Sanofi have lost 24.2% in the year-to-date period.Earnings of Sanofi beat estimates in each of the last four quarters, witnessing a surprise of 9.37%, on average. In the last reported quarter, SNY delivered an earnings surprise of 8.24%. This Little-Known Semiconductor Stock Could Be Your Portfolio’s Hedge Against Inflation Everyone uses semiconductors. But only a small number of people know what they are and what they do. If you use a smartphone, computer, microwave, digital camera or refrigerator (and that’s just the tip of the iceberg), you have a need for semiconductors. That’s why their importance can’t be overstated and their disruption in the supply chain has such a global effect. But every cloud has a silver lining. Shockwaves to the international supply chain from the global pandemic have unearthed a tremendous opportunity for investors. And today, Zacks' leading stock strategist is revealing the one semiconductor stock that stands to gain the most in a new FREE report. It's yours at no cost and with no obligation.>>Yes, I Want to Help Protect My Portfolio During the RecessionWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Sanofi (SNY): Free Stock Analysis Report BioMarin Pharmaceutical Inc. (BMRN): Free Stock Analysis Report SESEN BIO, INC. (SESN): Free Stock Analysis Report Morphic Holding, Inc. (MORF): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: ZACKS5 hr. 19 min. ago Related News

Are Stocks Gearing Up For A Big Q4 Rally?

A strong labor market is just one of several positives that investors are ignoring right now. But Kevin Matras can look behind the headlines and help you take full advantage of an improved fourth quarter and beyond. It’s been a rough year so far.40-year high inflation, which forced the Fed to aggressively raise rates in an effort to bring it down, has been weighing on stocks.As tough as this year has been, I’m reminded of the comparison that was made between the first half of this year, and the first half of 1970.This year’s first half performance (the S&P was down nearly -21%), was strikingly similar to that of 1970 (also down -21%). And in both periods, high inflation was an issue.But in the second half of 1970, the S&P was up 27%.Of course, that doesn’t mean that’s how it’ll go for the back half of this year. But it doesn’t mean it won’t either.Granted, the last few months haven’t been any easier. And there’s only 3 months left of this year. But with plenty of economic positives backstopping the economy right now, not the least of which is a strong labor market, there’s definitely a chance that the market is being too pessimistic.While we unofficially saw a recession after Q2 GDP fell by -0.6%, which followed Q1’s -1.6% (two quarters in a row of negative GDP is the technical definition of a recession), consumer demand remained strong throughout. So did corporate earnings. And the jobs market stayed sizzling hot.You can also see that in the GDI numbers (Gross Domestic Income), which measures U.S. economic activity via the income earned for these activities. Usually, the GDI and GDP (Gross Domestic Product) are statistically very similar. But unlike the GDP, the GDI was up in the first half of the year with a positive 0.5% annualized growth rate, while GDP was down.Will these two measures converge? If so, will GDP rise to meet GDI, or will GDI fall to meet GDP? Or maybe a little bit of both? TBD. But, at the moment, GDP forecasts are pointing to plus signs for the rest of the year.Q3 GDP is only expected to eke out a 0.3% gain. But Q4 is expected to be better, with full year estimates showing another year of growth. (It’s no longer a recession when the economy starts growing again.)And the Fed is predicting 2023 to be even better still with a 1.8% GDP growth rate.So there’s plenty of positives in the market right now. (The market happens to be ignoring them at the moment. But they are there nonetheless.)And with the market seemingly pricing in the worst-case scenario (deep and long recession), stocks are primed to rally once it looks like the worst-case scenario won’t come to pass (shallower and shorter recession). Peak Inflation Is Behind Us  One of the key factors which will likely determine where the market goes from here, will be inflation, and therefore, interest rates.Even though inflation is still too high, it has been ticking down for the last few months.Headline inflation, according to the Consumer Price Index (CPI), is at 8.3% y/y, with core inflation (less food & energy) at 6.3%. That’s down from its peak of 9.1% and 6.5%.While that dip is not a lot, and it’s a far cry from the Fed’s goal of getting it back down to 2%, the mere fact that it’s no longer making new highs, and instead is ticking lower, is a step in the right direction.(Oil prices, for example, have fallen sharply. After trading over $130 a barrel, crude oil is now trading at $82. That’s a decline of -37% in a matter of months. And that’s helping to ease inflation concerns.)A few months ago, many were expecting inflation to soar above 10% or more. Now, expectations are for it falling to 5-6% next year, with the core rate falling even lower.And that means the Fed may not have to raise rates as much as people are fearing.Are Stocks Undervalued? Let’s also not forget that valuations are down.The P/E ratio for the S&P is at multiyear lows, and is trading below its five-year average.And that makes stocks a bargain.Of course, if earnings drift lower, valuations will creep up. But there’s plenty of room for stocks to remain relatively cheap.And the earnings outlook is still forecasting growth.Add in another trillion dollars in stimulus between the CHIPS Act and the Inflation Reduction Act, and that should extend the growth outlook even further.More . . .------------------------------------------------------------------------------------------------------Alert: Buy These Ultimate Four Stocks There's still time to get in early. These aren't just 4 promising stocks. They were handpicked from hundreds of strong companies by Zacks' experts because they present the greatest upside for Q4:Stock #1: Little-known but highly influential tech stock with clients like Apple and Nvidia.Stock #2: Cutting-edge streaming company ready to break out. EPS estimates are up 25% in 30 days.Stock #3: An under-the-radar alternative energy company with estimates up to 70% in topline growth.Stock #4: Chemical company poised to become the dominant supplier of materials for EV batteries.Deadline to download our just-released Ultimate Four Special Report is Sunday, October 2.See Our “Ultimate” Stocks Now >> ------------------------------------------------------------------------------------------------------How Do Stocks Perform Around Midterms? Many are familiar with the Presidential Cycle and the markets. But many may not know that the Presidential Cycle covers all for years of a presidency.Of particular interest is the midterm portion of the cycle, which is where we are right now.And historically, it’s amazing to see how favorable this cycle is for investors at this point in time.Developed by Yale Hirsch, of the Stock Trader’s Almanac, the theory suggests that the stock market follows a pattern which correlates with a U.S. president’s four-year term. The election cycle consists of the post-election, midterm, pre-election, and election years. 2022 is an example of a midterm year, i.e., the second year in the 4-year presidential cycle.In the first two years after an election, the second year tends to be the weakest. In fact, it’s the weakest of all four years. Congressional elections take place – and with them, they bring the potential to shift the political backdrop.Hirsch discovered that wars, recessions, and bear markets (sound familiar?) tend to start in the first two years of a president’s term. This year, the market entered the weak spot of the cycle. And with an aggressive Fed, high inflation, and the ongoing Russia-Ukraine war, the weakness in stocks was amplified.Those who know their market history will find it somewhat unsurprising that the start to this year was rough. The second and third quarters of midterm years are historically quite weak. (History repeating itself once again.)But more prosperous times typically lie ahead in the latter half of the cycle.In fact, we’re entering the most bullish part of the calendar -- Q4 of year 2 in the 4-year presidential cycle (the second-strongest quarter of all 16 quarters), sporting an average return of 6.6% (since 1950); and Q1 of year 3 (the strongest quarter of all 16 quarters), with a 7.4% average gain.And when we factor in that the third year of the presidential cycle has historically witnessed the best performance of all four years, the outlook for stocks looks even brighter.Now Is The Time To Start Building Your Dream Portfolio  With stocks near their lows, now is the time to start building your dream portfolio.As legendary investor Warren Buffett once said, “be greedy when others are fearful.”And there’s plenty of fear in the market right now.But it should also be known that a large part of any market recovery typically comes at the very beginning.Whether that’s now, next week, or next month, etc., we’re definitely much closer to the bottom than we were just a few short weeks or months ago.To increase your odds of getting in at the bottom, you should always be scanning for new stocks to get into.True, when the market is falling, and economic conditions weaken, there will be fewer stocks coming through your screens. That’s just the way it is.But there will always be great stocks coming through. And savvy investors who diligently stay engaged in the market, even when times are tougher, will find those gems when others have given up.And since you are doing this regularly, you won’t miss out when the market turns around. Of course, they won’t all be winners. You may get into a new stock that goes down. But that’s OK. If you keep your losses small, you won’t do any damage to your portfolio.But you will inevitably find yourself in some spectacular picks at precisely the right time.And if you don’t think there’s money to be made during tough times like these, just know that YTD, even though the major indexes are all down, there are 689 stocks that are by 10% or more; 495 that are up by 20% or more; 213 up by 50% or more, and 85 that are up by 100% or more.Increasing Your Odds Of Success  Of course, picking winning stocks does require a degree of skill.If you keep looking at the wrong things to pick stocks with, you’ll rarely if ever get into the winners.But picking winning stocks is easier than you think.For example, did you know that stocks with a Zacks Rank #1 Strong Buy have beaten the market in 28 of the last 34 years with an average annual return of 25% per year? That's more than 2 x the S&P with an annual win ratio of more than 82%.That includes 3 bear markets and 4 recessions.And did you know that stocks in the top 50% of Zacks Ranked Industries outperform those in the bottom 50% by a factor of 2 to 1? There's a reason why they say that half of a stock's price movement can be attributed to the group that it's in. Because it's true!Those two things will give any investor a huge probability of success and put you well on your way to beating the market.But you still have to narrow that list down to the handful of stocks you can buy at any one time.And that’s where the professional expertise of our editors comes in.One of the best ways to begin picking better stocks is to see what the pros are doing – the pros who use these methods to select the best stocks to buy.Whether you’re a growth investor, or a value investor, prefer fast-paced momentum stocks, or mature dividend-paying income stocks, there are certain rules the experts follow to maximize their gains.This applies to large-caps and small-caps, biotech and high-tech, ETFs, stocks under $10, stocks about to surprise, even options, and everything in between.Regardless of which one fits your personal style of trade, just be sure you’re following proven profitable methods that work, from experts who have demonstrated their ability to beat the market.The best part about these strategies is that all of the hard work is done for you. There’s no guesswork involved. Just follow the experts and start getting into better stocks on your very next trade.The Easiest, Fastest Way to Get Started  Download our just-released Ultimate Four Special Report. It's simple. Gain access to all our recommended stocks for the next 30 days. Take part in the experience we call Zacks Ultimate.Total cost? Only $1. I'm not kidding.And there's not a cent of further obligation.Get started now and you'll receive our just-released Ultimate Four Special Report.It names and explains 4 stocks with strong fundamentals that are hand-picked by our experts to have the biggest upsides for Q4. And despite inflation there couldn’t be a better time to get aboard. Stocks are substantially undervalued, but the U.S. economy is much better than most people realize, with strong consumer demand, robust job market and solid corporate earnings.In particular, these 4 stocks are riding trends that could prove very lucrative for investors...Stock #1: It’s one of the world’s most influential tech stocks, but most investors have never heard of it. Revenue jumped 44% thanks to extreme demand for its products from other tech companies like Apple.Stock #2: This cutting-edge entertainment company is ready to break out. Shares are already climbing after a pullback earlier in the year, and with EPS estimates up 25% in the last 30 days, big gains are on the horizon.Stock #3: An under-the-radar alternative energy company is poised to leap into the headlines. Analysts are calling for a massive 70% in topline growth – and government stimulus could push revenues even higher.Stock #4: The surging electric vehicle industry will give this chemical company a major boost. With operations on 5 continents, it could become a dominant supplier of materials for a new generation of EV batteries.Don’t miss this chance to get in early on our latest Ultimate Four. We’re limiting the number of people who share that Special Report. There’s a hard deadline - the opportunity to download it ends midnight Monday, October 2nd.Start Zacks Ultimate and see our Ultimate Four stocks now >> Thanks and good trading,KevinKevin Matras serves as Executive Vice President of Zacks.com and is responsible for all of its leading products for individual investors. He invites you to download Zacks’ newly released Ultimate Four Special Report. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: ZACKS5 hr. 19 min. ago Related News

Helen of Troy (HELE) Q2 Earnings Coming Up: Things to Note

Helen of Troy's (HELE) fiscal second-quarter performance will likely reflect the impacts of high inflation and supply chain disruptions. Strength in the Home & Outdoor category is aiding. Helen of Troy Limited HELE is likely to register top-line growth when it reports second-quarter fiscal 2023 earnings on Oct 5, 2022. The Zacks Consensus Estimate for quarterly revenues is pegged at $519.1 million, suggesting an increase of 9.2% from the figure reported in the prior-year quarter.Helen of Troy’s bottom line is likely to decline year over year. The Zacks Consensus Estimate for quarterly earnings dropped by a couple of cents in the past 30 days to $2.22 per share. The projection indicates a decline of 16.2% from the year-ago quarter’s reported figure. Helen of Troy has a trailing four-quarter earnings surprise of 22.5%, on average. This consumer products company delivered an earnings surprise of 24.2% in the last reported quarter.Things To NoteHelen of Troy has been witnessing pressure from the rising inflationary environment. The company is also bearing the brunt of supply chain-related disruptions. The shift in consumer buying patterns amid rising costs is a headwind. Helen of Troy’s international presence exposes it to risks of unfavorable currency rates.In its last earnings call, management highlighted that it expects a mid-teen decline in second-quarter fiscal 2023 adjusted earnings per share, mainly caused by reduced adjusted operating margin and increased interest expense. The company anticipates low double-digit growth in the to-be-reported quarter, as the year-ago quarter included the largest adverse impact from the Environmental Protection Agency ("EPA") matter.Helen of Troy Limited Price and EPS Surprise  Helen of Troy Limited price-eps-surprise | Helen of Troy Limited Quote Helen of Troy is benefiting from strength in the Home & Outdoor category. In this regard, contributions from Osprey (acquired in December 2021) brand fuel category growth. Helen of Troy is making major investments in key areas like consumer-centric innovation, digital marketing, enhanced production, distribution capacity and direct-to-consumer channels. The company is on track with cost savings endeavors to counter inflation and supply chain disruptions.What the Zacks Model UnveilsOur proven model does not predict an earnings beat for Helen of Troy this time. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.Helen of Troy has an Earnings ESP of -3.50% and carries a Zacks Rank #4 (Sell).Stocks With Favorable CombinationHere are some companies you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat:Kellogg Company K currently has an Earnings ESP of +1.04% and a Zacks Rank #3. K is expected to register top-line growth when it reports third-quarter 2022 numbers. The Zacks Consensus Estimate for Kellogg's quarterly revenues is pegged at $3.8 billion, which suggests growth of around 4% from the prior-year quarter’s reported figure. You can see the complete list of today’s Zacks #1 Rank stocks here.The Zacks Consensus Estimate for Kellogg's quarterly earnings has dropped by a penny in the past 30 days to 96 cents per share, suggesting a decline of 11.9% from the year-ago quarter’s tally. K delivered an earnings beat of 13.3%, on average, in the trailing four quarters.Sysco Corporation SYY currently has an Earnings ESP of +0.36% and a Zacks Rank #3. The company is likely to register top-and bottom-line improvement when it reports first-quarter fiscal 2023 numbers. The Zacks Consensus Estimate for the quarterly EPS of 99 cents suggests a 19.3% improvement from the figure reported in the year-ago quarter.The Zacks Consensus Estimate for Sysco’s quarterly revenues is pegged at $18.6 billion, indicating an improvement of 13.1% from the figure reported in the prior-year quarter. SYY has a trailing four-quarter earnings surprise of 3.6%, on average.Beyond Meat BYND currently has an Earnings ESP of +9.23% and a Zacks Rank of 3. The company is likely to register a rise in the top line when it reports third-quarter 2022 results. The Zacks Consensus Estimate for BYND’s quarterly revenues is pegged at $113.3 million, which suggests a jump of 6.4% from the figure reported in the prior-year quarter.The consensus mark for Beyond Meat’s bottom line improved by a penny in the past 30 days to a loss of $1.10 per share, compared with a loss of 87 cents reported in the year-ago quarter.Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar. This Little-Known Semiconductor Stock Could Be Your Portfolio’s Hedge Against Inflation Everyone uses semiconductors. But only a small number of people know what they are and what they do. If you use a smartphone, computer, microwave, digital camera or refrigerator (and that’s just the tip of the iceberg), you have a need for semiconductors. That’s why their importance can’t be overstated and their disruption in the supply chain has such a global effect. But every cloud has a silver lining. Shockwaves to the international supply chain from the global pandemic have unearthed a tremendous opportunity for investors. And today, Zacks' leading stock strategist is revealing the one semiconductor stock that stands to gain the most in a new FREE report. It's yours at no cost and with no obligation.>>Yes, I Want to Help Protect My Portfolio During the RecessionWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Kellogg Company (K): Free Stock Analysis Report Sysco Corporation (SYY): Free Stock Analysis Report Helen of Troy Limited (HELE): Free Stock Analysis Report Beyond Meat, Inc. (BYND): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: ZACKS6 hr. 35 min. ago Related News

What"s in the Offing for Lamb Weston"s (LW) in Q1 Earnings?

Lamb Weston's (LW) first-quarter fiscal 2023 performance will likely reflect gains from recovering foodservice demand. Focus on pricing actions amid rising cost concerns is a breather. Lamb Weston Holdings, Inc. LW is likely to register top-and bottom-line growth when it reports first-quarter fiscal 2022 earnings on Oct 5. The Zacks Consensus Estimate for quarterly revenues is pegged at $1,141 million, suggesting a rise of nearly 16% from the prior-year quarter’s reported figure.The Zacks Consensus Estimate for quarterly earnings has remained unchanged at 52 cents per share in the past 30 days, suggesting an increase from 20 cents reported in the year-ago quarter. The frozen potato products company has a trailing four-quarter earnings surprise of 24.4%, on average. LW delivered an earnings surprise of 27.5% in the last reported quarter.Things To ConsiderLamb Weston has been benefiting from the recovery in the Foodservice business. The continued rebound in demand from full-service restaurants and non-commercial channels like lodging and hospitality, healthcare, schools and universities, sports and entertainment and workplace environments has been aiding volumes. Lamb Weston is gaining on its robust price/mix amid a rising inflationary environment. The company’s constant efforts to boost offerings and expand capacity bode well amid rising demand for snacks and fries. We believe that the persistence of these aspects bodes well for the quarter to be reported.Lamb Weston Price and EPS Surprise  Lamb Weston price-eps-surprise | Lamb Weston QuoteIn its last earnings call, management highlighted that inflation is likely to remain a major threat to the company’s costs and demand for fries. Management expects the gross margin to remain under pressure in the first half of fiscal 2023 due to considerable inflation for key production inputs, transportation and packaging and rising raw potato costs on a per-pound basis. Also, the adverse impacts of supply-chain hurdles, resulting in operational bottlenecks like labor and commodities shortage threaten the company’s margin. The persistence of these factors might be a concern for Lamb Weston’s performance in the fiscal first quarter. What the Zacks Model UnveilsOur proven model doesn’t conclusively predict an earnings beat for Lamb Weston this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.Lamb Weston has an Earnings ESP of 0.00% and carries a Zacks Rank #2.Stocks With Favorable CombinationHere are some companies you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat:Kellogg Company K currently has an Earnings ESP of +1.04% and a Zacks Rank #3. K is expected to register top-line growth when it reports third-quarter 2022 numbers. The Zacks Consensus Estimate for Kellogg's quarterly revenues is pegged at $3.8 billion, which suggests growth of around 4% from the prior-year quarter’s reported figure. You can see the complete list of today’s Zacks #1 Rank stocks here.The Zacks Consensus Estimate for Kellogg's quarterly earnings has dropped by a penny in the past 30 days to 96 cents per share, suggesting a decline of 11.9% from the year-ago quarter’s tally. K delivered an earnings beat of 13.3%, on average, in the trailing four quarters.Sysco Corporation SYY currently has an Earnings ESP of +0.36% and a Zacks Rank #3. The company is likely to register top-and bottom-line improvement when it reports first-quarter fiscal 2023 numbers. The Zacks Consensus Estimate for the quarterly EPS of 99 cents suggests a 19.3% improvement from the figure reported in the year-ago quarter.The Zacks Consensus Estimate for Sysco’s quarterly revenues is pegged at $18.6 billion, which indicates an improvement of 13.1% from the figure reported in the prior-year quarter. SYY has a trailing four-quarter earnings surprise of 3.6%, on average.Beyond Meat BYND currently has an Earnings ESP of +9.23% and a Zacks Rank of 3. The company is likely to register a rise in the top line when it reports third-quarter 2022 results. The Zacks Consensus Estimate for BYND’s quarterly revenues is pegged at $113.3 million, which suggests a jump of 6.4% from the figure reported in the prior-year quarter.The consensus mark for Beyond Meat’s bottom line improved by a penny in the past 30 days to a loss of $1.10 per share, compared with a loss of 87 cents reported in the year-ago quarter.Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar. This Little-Known Semiconductor Stock Could Be Your Portfolio’s Hedge Against Inflation Everyone uses semiconductors. But only a small number of people know what they are and what they do. If you use a smartphone, computer, microwave, digital camera or refrigerator (and that’s just the tip of the iceberg), you have a need for semiconductors. That’s why their importance can’t be overstated and their disruption in the supply chain has such a global effect. But every cloud has a silver lining. Shockwaves to the international supply chain from the global pandemic have unearthed a tremendous opportunity for investors. And today, Zacks' leading stock strategist is revealing the one semiconductor stock that stands to gain the most in a new FREE report. It's yours at no cost and with no obligation.>>Yes, I Want to Help Protect My Portfolio During the RecessionWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Kellogg Company (K): Free Stock Analysis Report Sysco Corporation (SYY): Free Stock Analysis Report Lamb Weston (LW): Free Stock Analysis Report Beyond Meat, Inc. (BYND): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: ZACKS6 hr. 35 min. ago Related News

Here"s Why Should You Stay Invested in Primerica (PRI)

Compelling portfolio, strong market presence, solid capital position poise Primerica (PRI) for growth. Primerica, Inc.’s PRI compelling portfolio, strong market presence, solid capital position and favorable growth estimates make it worth retaining in one’s portfolio.Zacks Rank & Price PerformancePrimerica currently carries a Zacks Rank #3 (Hold). Year to date, the stock has lost 18.9%, compared with the industry’s decline of 9.1%.Image Source: Zacks Investment ResearchNorthbound Estimate RevisionThe Zacks Consensus Estimate for 2023 has moved 1 cent north in the past 30 days, reflecting analyst optimism.Growth ProjectionsThe Zacks Consensus Estimate for Primerica’s 2023 earnings is pegged at $13.84, indicating a 22.7% increase from the year-ago reported figure on 6.2% higher revenues of $2.9 billion.Growth DriversPrimerica is the second-largest issuer of term-life insurance coverage in North America, with $900 billion policies in force in 2022. Strong demand for protection products should drive sales growth and policy persistency. PRI’s strong business model makes it well poised to cater to the middle market's increased demand for financial security. This, in turn, should continue to boost operational performance.PRI estimates adjusted direct premium at Term Life, its biggest segment, to increase 7% in the third quarter of 2022 while sales in the second half are expected to grow 4-5%.  However, given market volatility, PRI expects third-quarter ISP sales to decline in the mid-20% range, asset-based net revenues to decline about $3 million and sales-based net revenues to decline about $10 million year over year.Licensed representatives play a major role in driving operational results for PRI. The insurer thus remains focused on growing licensed representatives.With the U.S. mortgage distribution business gaining traction, Primerica remains focused on expanding distribution. However, given an improving interest rate environment, PRI expects growth to be muted in this segment.However, PRI projects insurance and other operating expenses to increase 8% and 6%, respectively, in the third and fourth quarters of 2022.The insurer had solid liquidity with cash and cash equivalents of $400 million at second-quarter 2022 end. Primerica Life Insurance Company’s statutory risk-based capital ratio was about 460% as of Jun 30, 2022.Primerica has been strengthening its balance sheet by improving its leverage ratio. PRI scores strongly with credit rating agencies.Banking on the continued solid performance of Term Life and ISP businesses, Primerica boasts an impressive dividend history. It has hiked dividends 10 times in the last nine years. Primerica looks to buy back $356 million worth of shares in 2022. PRI expects the Term Life business to be the primary source of deployable capitalThe company has a VGM Score of B.Stocks to ConsiderSome better-ranked stocks from the industry are Reinsurance Group of America RGA, Brighthouse Financial BHF and Voya Financial VOYA.Reinsurance Group delivered an earnings surprise of 112.5% in the last reported quarter.  Year to date, the insurer has rallied 13.9%.  RGA sports Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.The Zacks Consensus Estimate for RGA’s 2022 and 2023 earnings implies a respective increase of 1,057% and 20.5% from the year-ago reported number.Brighthouse Financial’s earnings surpassed estimates in each of the last four quarters, the average beat being 42.34%. Year to date, Brighthouse Financial has lost 15.4%.The Zacks Consensus Estimate for BHF’s 2022 and 2023 earnings has moved 17.3% and 3.6% north, respectively, in the past 30 days.The bottom line of Voya surpassed earnings estimates in three of the last four quarters and missed in one, the average being 10.81%. Year to date, the insurer has lost 8.1%.The Zacks Consensus Estimate for Voya’s 2022 and 2023 earnings has moved 3.4% and 0.7% north, respectively, in the past 30 days. This Little-Known Semiconductor Stock Could Be Your Portfolio’s Hedge Against Inflation Everyone uses semiconductors. But only a small number of people know what they are and what they do. If you use a smartphone, computer, microwave, digital camera or refrigerator (and that’s just the tip of the iceberg), you have a need for semiconductors. That’s why their importance can’t be overstated and their disruption in the supply chain has such a global effect. But every cloud has a silver lining. Shockwaves to the international supply chain from the global pandemic have unearthed a tremendous opportunity for investors. And today, Zacks' leading stock strategist is revealing the one semiconductor stock that stands to gain the most in a new FREE report. It's yours at no cost and with no obligation.>>Yes, I Want to Help Protect My Portfolio During the RecessionWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Reinsurance Group of America, Incorporated (RGA): Free Stock Analysis Report Primerica, Inc. (PRI): Free Stock Analysis Report Voya Financial, Inc. (VOYA): Free Stock Analysis Report Brighthouse Financial, Inc. (BHF): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: ZACKS6 hr. 35 min. ago Related News

What Makes Banco De Chile (BCH) a New Buy Stock

Banco De Chile (BCH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. Banco De Chile (BCH) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Since a changing earnings picture is a powerful factor influencing near-term stock price movements, the Zacks rating system is very useful for individual investors. They may find it difficult to make decisions based on rating upgrades by Wall Street analysts, as these are mostly driven by subjective factors that are hard to see and measure in real time.Therefore, the Zacks rating upgrade for Banco De Chile basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price.Most Powerful Force Impacting Stock PricesThe change in a company's future earnings potential, as reflected in earnings estimate revisions, and the near-term price movement of its stock are proven to be strongly correlated. The influence of institutional investors has a partial contribution to this relationship, as these big professionals use earnings and earnings estimates to calculate the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their transaction of large amounts of shares then leads to price movement for the stock.For Banco De Chile, rising earnings estimates and the consequent rating upgrade fundamentally mean an improvement in the company's underlying business. And investors' appreciation of this improving business trend should push the stock higher.Harnessing the Power of Earnings Estimate RevisionsAs empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, tracking such revisions for making an investment decision could be truly rewarding. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions.The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here >>>>.Earnings Estimate Revisions for Banco De ChileFor the fiscal year ending December 2022, this company is expected to earn $2.79 per share, which is a change of 13.9% from the year-ago reported number.Analysts have been steadily raising their estimates for Banco De Chile. Over the past three months, the Zacks Consensus Estimate for the company has increased 21%.Bottom LineUnlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of 'buy' and 'sell' ratings for its entire universe of more than 4000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a 'Strong Buy' rating and the next 15% get a 'Buy' rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term.You can learn more about the Zacks Rank here >>>The upgrade of Banco De Chile to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term. This Little-Known Semiconductor Stock Could Be Your Portfolio’s Hedge Against Inflation Everyone uses semiconductors. But only a small number of people know what they are and what they do. If you use a smartphone, computer, microwave, digital camera or refrigerator (and that’s just the tip of the iceberg), you have a need for semiconductors. That’s why their importance can’t be overstated and their disruption in the supply chain has such a global effect. But every cloud has a silver lining. Shockwaves to the international supply chain from the global pandemic have unearthed a tremendous opportunity for investors. And today, Zacks' leading stock strategist is revealing the one semiconductor stock that stands to gain the most in a new FREE report. It's yours at no cost and with no obligation.>>Yes, I Want to Help Protect My Portfolio During the RecessionWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Banco De Chile (BCH): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: ZACKS6 hr. 35 min. ago Related News

What Makes Immuneering Corporation (IMRX) a New Buy Stock

Immuneering Corporation (IMRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. Immuneering Corporation (IMRX) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Since a changing earnings picture is a powerful factor influencing near-term stock price movements, the Zacks rating system is very useful for individual investors. They may find it difficult to make decisions based on rating upgrades by Wall Street analysts, as these are mostly driven by subjective factors that are hard to see and measure in real time.Therefore, the Zacks rating upgrade for Immuneering Corporation basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price.Most Powerful Force Impacting Stock PricesThe change in a company's future earnings potential, as reflected in earnings estimate revisions, and the near-term price movement of its stock are proven to be strongly correlated. The influence of institutional investors has a partial contribution to this relationship, as these big professionals use earnings and earnings estimates to calculate the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their transaction of large amounts of shares then leads to price movement for the stock.For Immuneering Corporation, rising earnings estimates and the consequent rating upgrade fundamentally mean an improvement in the company's underlying business. And investors' appreciation of this improving business trend should push the stock higher.Harnessing the Power of Earnings Estimate RevisionsAs empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, tracking such revisions for making an investment decision could be truly rewarding. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions.The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here >>>>.Earnings Estimate Revisions for Immuneering CorporationFor the fiscal year ending December 2022, this company is expected to earn -$1.99 per share, which is a change of 19.1% from the year-ago reported number.Analysts have been steadily raising their estimates for Immuneering Corporation. Over the past three months, the Zacks Consensus Estimate for the company has increased 7.5%.Bottom LineUnlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of 'buy' and 'sell' ratings for its entire universe of more than 4000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a 'Strong Buy' rating and the next 15% get a 'Buy' rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term.You can learn more about the Zacks Rank here >>>The upgrade of Immuneering Corporation to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term. This Little-Known Semiconductor Stock Could Be Your Portfolio’s Hedge Against Inflation Everyone uses semiconductors. But only a small number of people know what they are and what they do. If you use a smartphone, computer, microwave, digital camera or refrigerator (and that’s just the tip of the iceberg), you have a need for semiconductors. That’s why their importance can’t be overstated and their disruption in the supply chain has such a global effect. But every cloud has a silver lining. Shockwaves to the international supply chain from the global pandemic have unearthed a tremendous opportunity for investors. And today, Zacks' leading stock strategist is revealing the one semiconductor stock that stands to gain the most in a new FREE report. It's yours at no cost and with no obligation.>>Yes, I Want to Help Protect My Portfolio During the RecessionWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Immuneering Corporation (IMRX): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: ZACKS6 hr. 35 min. ago Related News